Bausch Health Companies Inc.
Bausch Health Companies Inc. (BHC) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
bhc · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Bausch Health Companies Inc. (BHC) measures how much investors pay for each dollar of the company's trailing earnings. BHC's current PE ratio of N/A is calculated by dividing its stock price of $5.25 by its TTM earnings per share of -$3.19.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 8 fiscal years · Front-end computedMinQ1 · 25%14.3x
MedianQ3 · 75%89.1x
Max
At N/A, BHC's current P/E is lower than in 0% of its annual fiscal year readings over the past 8 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Bausch Health Companies Inc.You BHC | $2.0B | N/A | — | -$3.19 |
 Alvotech ALVO | $1.2B | 51.30x | +104.5% | $0.10 |
 ANI Pharmaceuticals, Inc. ANIP | $1.8B | 20.21x | -19.5% | $3.91 |
 Beam Therapeutics Inc. BEAM | $3.0B | N/A | — | -$0.81 |
 Concentra Group Holdings Parent, Inc. CON | $3.3B | 14.42x | -42.5% | $1.36 |
 Catalyst Pharmaceuticals, Inc. CPRX | $3.8B | 13.32x | -46.9% | $1.75 |
 Haemonetics Corporation HAE | $3.3B | 26.20x | +4.4% | $2.06 |
Industry Average 5 peers with valid PE | — | 25.09x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 16.14x | $0.43 | — | |
2024-12-31 FY2024 | — | $-0.13 | — | |
2023-12-31 FY2023 | — | $-1.62 | — | |
2022-12-31 FY2022 | — | $-0.62 | — | |
2021-12-31 FY2021 | — | $-2.64 | — | |
2020-12-31 FY2020 | — | $-1.57 | — | |
2019-12-31 FY2019 | — | $-5.06 | — | |
2018-12-31 FY2018 | — | $-11.86 | — | |
2017-12-31 FY2017 | 3.03x | $6.86 | — | |
2016-12-31 FY2016 | — | $-6.94 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Bausch Health Companies Inc. (BHC) measures how much investors pay for each dollar of the company's trailing earnings. BHC's current PE ratio of N/A is calculated by dividing its stock price of $5.25 by its TTM earnings per share of -$3.19.
Frequently asked questions
BHC pe ratio · 6 questionsBHC's current PE ratio is N/A as of 2026-06-08, based on a stock price of $5.25 and TTM EPS of -$3.19. Data sourced from Financial Modeling Prep via BHC's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Bausch Health Companies Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08